Major EHR vendor Cerner would like to see the SMART on FHIR protocol take off as it seeks to make genomic data just another element of a patient's record.
Research presented at AMIA this month demonstrated a computing method for predicting family pedigrees by mining demographic data in electronic health records.
In a poster presented at AMIA, just one-third of IGNITE participants had external structured genomic test results in their EHRs to inform clinical decision support.
Led by researchers at BBMRI-ERIC, the effort intends to clarify how entities should share data, including genomics information, across institutions and countries.
The EHR giant says it's responding to customer demand for integrating genomic data into patient records and workflows without overwhelming front-line clinicians.
Starting in early 2019, Yale plans to sign up at least 100,000 patients to analyze their genomes and EHR data for research and return of clinically actionable results.
The framework, called HEAL, could be used as an early screening test for AAA and as a personal health management tool. In addition, it may be applicable to other complex diseases.
The system relies on the use of scannable safety code cards containing patient data, along with a web portal and automated analysis tools that deliver customized diagnostic reports.
DeCode's new offering adds to an ongoing controversy over whether people in the island country have a right to know if they are at increased risk for disease.
Finland-based Tieto and Swiss firm BC Platforms will jointly develop technology for integrating genomic and clinical data in the Northern European market.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.